alpha-MSH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-20. Numbers and descriptions here follow the published literature rather than marketing material.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Iron-deficiency anemia is confirmed by tests that include serum ferritin, serum iron level, serum transferrin, and total iron binding capacity. A low serum ferritin is most commonly found. However, serum ferritin can be elevated by any chronic inflammation and thus is not consistently decreased in iron-deficiency anemia. Serum iron levels may be measured, but serum iron concentration is not as reliable as the measurement of both serum iron and serum iron-binding protein levels. The percentage of iron saturation (or transferrin saturation index or percent) can be measured by dividing the level of serum iron by total iron binding capacity and is a value that can help to confirm the diagnosis of iron-deficiency anemia; however, other conditions must also be considered, including other types of anemia. Another finding that can be used is the level of red blood cell distribution width. During haemoglobin synthesis, trace amounts of zinc will be incorporated into protoporphyrin in the place of iron which is lacking. Protoporphyrin can be separated from its zinc moiety and measured as free erythrocyte protoporphyrin, providing an indirect measurement of the zinc-protoporphyrin complex. The level of free erythrocyte protoporphyrin is expressed in either μg/dl of whole blood or μg/dl of red blood cells. An iron insufficiency in the bone marrow can be detected very early by a rise in free erythrocyte protoporphyrin. Further testing may be necessary to differentiate iron-deficiency anemia from other disorders, such as thalassemia minor.
Chancellor Hunt says that cuts in public spending will cost "a great deal less" than allowing Russia to win. 25 April Labour pledges to renationalise most rail services within five years if it wins the next general election. The SNP's power-sharing deal with the Scottish Greens collapses. Shoplifting is reported to have hit a record high in 2023, with more than 430,000 offences recorded. This figure is up by more than one-third compared to 2022, and likely represents a fraction of the true number of incidents. In the High Court, Laurence Fox is ordered to pay £180,000 in libel damages to former Stonewall trustee Simon Blake and drag artist Crystal. The Environment Minister, Robbie Moore says "Additional time will be needed to efficiently and effectively roll out the schemes across the UK," as the Cash for Bottle deposit scheme is delayed until October 2027. Moroccan asylum seeker Ahmed Alid is convicted of the murder of Terence Carney, who was stabbed multiple times in an attack at Hartlepool in October 2023. Gary Roden resigns as the general manager of Co-op Live following a series of problems and delays at the venue. 26 April A trial begins of the first personalised melanoma vaccine, based on mRNA, the same technology as current COVID vaccines. Buckingham Palace announces that King Charles will resume his public duties from the following week after making good progress with his cancer treatment. An inquest into the 2020 Reading stabbings concludes they could have been avoided but for problems with the sharing of intelligence between authorities.
The use of C–H functionalization in the synthesis of lithospheric acid exemplifies the site- and stereoselective capabilities of using MPAA ligands in these reactions. As the penultimate step, the intermolecular C–H olefination introduces almost double the complexity into the compound enabling the highly convergent synthesis.
Sources: en.wikipedia.org
Beryllium (4Be) has 11 known isotopes and 3 known isomers, but only one of these isotopes (9Be) is stable and a primordial nuclide. As such, beryllium is considered a monoisotopic element. It is also a mononuclidic element, because its other isotopes have such short half-lives that none are primordial and their abundance is very low. Beryllium is unique as being the only monoisotopic element with an even number of protons (even atomic number) and also has an odd number of neutrons; the 25 other monoisotopic elements all have odd numbers of protons (odd atomic number), and even of neutrons, so the total mass number is still odd. Of the 10 radioisotopes of beryllium, the most stable are 10Be with a half-life of 1.387 million years and 7Be with a half-life of 53.22 days. All other radioisotopes have half-lives shorter than 15 seconds. The 1:1 neutron–proton ratio seen in stable isotopes of many light elements (up to oxygen, and in elements with even atomic number up to calcium) is prevented in beryllium by the extreme instability of 8Be toward splitting into two 4He nuclei, which may be seen either alpha decay or a type of fission; in any case the half-life is only 8.2×10−17 s, short enough to normally be considered unbound. This, as with the relative instability of all lithium, beryllium, and boron isotopes, is favored due to the extremely tight binding of the helium-4 nucleus. Beryllium is prevented from having a stable isotope with 4 protons and 6 neutrons by the very lopsided neutron–proton ratio for such a light element.
In his free time, Thomas visited the cinema in Uplands, took walks along Swansea Bay, and frequented Swansea's pubs, especially the Antelope and the Mermaid Hotels in Mumbles. In the Kardomah Café, close to the newspaper office in Castle Street, he met his creative contemporaries, including his friend the poet Vernon Watkins and the musician and composer, Daniel Jones with whom, as teenagers, Thomas had helped to set up the "Warmley Broadcasting Corporation". This group of writers, musicians and artists became known as "The Kardomah Gang". This was also the period of his friendship with Bert Trick, a local shopkeeper, left-wing political activist and would-be poet, and with the Rev. Leon Atkin, a Swansea minister, human rights activist and local politician. In 1933, Thomas visited London for probably the first time.
E.; van Donzel, E. & Heinrichs, W. P. (eds.). The Encyclopaedia of Islam, Second Edition. Volume X: T–U. Leiden: E. J. Brill. pp. 763–764. ISBN 978-90-04-11211-7. Wellhausen, Julius (1927). The Arab Kingdom and Its Fall. Translated by Margaret Graham Weir. Calcutta: University of Calcutta.
Sources: en.wikipedia.org
While modern identification of mushrooms is quickly becoming molecular, the standard methods for identification are still used by most and have developed into a fine art harking back to medieval times and the Victorian era, combined with microscopic examination. The presence of juices upon breaking, bruising-reactions, odors, tastes, shades of color, habitat, habit, and season are all considered by both amateur and professional mycologists. Tasting and smelling mushrooms carries its own hazards because of poisons and allergens. Chemical tests are also used for some genera. In general, identification to genus can often be accomplished in the field using a local field guide. Identification to species, however, requires more effort. A mushroom develops from a button stage into a mature structure, and only the latter can provide certain characteristics needed for the identification of the species. However, over-mature specimens lose features and cease producing spores. Many novices have mistaken humid water marks on paper for white spore prints, or discolored paper from oozing liquids on lamella edges for colored spored prints.
John Calvin Giddings (September 26, 1930 – October 24, 1996) was a Distinguished Professor of chemistry at the University of Utah. Giddings received a B.S. degree from Brigham Young University in 1952 and a PhD from the University of Utah in 1954. Following postdoctoral work at the University of Utah and the University of Wisconsin, he joined the faculty of the University of Utah as assistant professor of chemistry in 1957. He became associate professor in 1959, research professor in 1962, and professor in 1966. Giddings authored or co-authored more than 400 publications and edited 32 books in the field of chemistry. He was executive editor of the journal Separation Science and Technology, and the editor of the series Advances in chromatography. Gidding's work in separation sciences shed light on the chromatographic processes, as well as other separation techniques, including non-equilibrium, diffusion & eddy diffusion, pressure changes, flow in paper and thin-layer chromatography, preparative-scale, and programmed-temperature gas chromatography (GC), exclusion chromatography, electrophoresis, and the generation of non-gaussian zones. He developed understanding of the optimization of multicomponent chromatography especially in 2D separations. His vision of the capabilities of high-pressure chromatographic systems evolved into High Performance Liquid Chromatography (HPLC), by suggesting to reduce particle size of the columns' packing in liquid chromatography.
Humanin is a micropeptide encoded in the mitochondrial genome by the 16S ribosomal RNA gene, MT-RNR2. Its structure contains a three-turn α-helix, and no symmetry. In in vitro and animal models, it appears to have cytoprotective effects.
Some psychedelics, including LSD, are metabolized by the cytochrome P450 enzyme CYP2D6. Concurrent use of selective serotonin reuptake inhibitors (SSRIs), some of which are potent inhibitors of CYP2D6, with LSD might heighten the risk of serotonin syndrome. However, according to other researchers, there is no risk of serotonin syndrome combining psychedelics like LSD and psilocybin with SSRIs. Chronic usage of SSRIs, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) is believed to diminish the subjective effects of psychedelics, likely due to 5-HT2A receptor downregulation or desensitization induced by elevated serotonin levels. However, a clinical study found that administration of LSD to people taking paroxetine, an SSRI and strong CYP2D6 inhibitor, increased LSD exposure by about 1.5-fold, was well-tolerated, and did not modify the pleasant subjective effects or physiological effects of LSD, whereas negative effects of LSD, including "bad drug effect", anxiety, and nausea, were reduced. Similarly, a clinical study with LSD found that LSD levels were 75% higher in people with non-functional CYP2D6 (poor metabolizers) compared to those with functional CYP2D6. In contrast to certain other psychedelics, MAOIs do not inhibit the metabolism of or potentiate the effects of LSD and instead reduce its effects. Interactions between psychedelics and antipsychotics or anticonvulsants are not well-documented; however, co-use with mood stabilizers like lithium may induce seizures and dissociative effects, particularly in individuals with bipolar disorder.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.